中國光大控股(00165.HK):建議於中國發行多品種債務融資工具
格隆匯7月11日丨中國光大控股(00165.HK)發佈公告,公司今日向中國銀行間市場交易商協會(“交易商協會”)作出申請,以註冊總金額不高於人民幣200億元且公司將於適當時候分多個批次發行的多品種債務融資工具(“債務融資工具”),建議發行將在交易商協會出具的接受註冊通知書的日期起計爲期兩年內進行。由於申請正在處理中,申請能否及何時獲批準,以及註冊債務融資工具何時將完成仍未確定。
倘進行建議發行,接受註冊通知書項下債務融資工具發行的確切時間、期限及規模以及條款將取決於發行時的現行市況,債務融資工具的票面利率將透過集中簿記建檔方式釐定。於發行後,債務融資工具將於全國銀行間債券市場進行交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.